Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers

Healthy Volunteers Clinical Trial

Official title:

Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in Healthy Volunteers

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04594395
• Other study ID #: 10000083
• Secondary ID: 000083-I
• Status: Withdrawn
• Start date: September 24, 2021
• Est. completion date: September 30, 2021

Study information

• Verified date: October 2021
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

In early 2020, many people thought Cambodia would have a serious COVID-19 outbreak due to the high number of Chinese travelers going to Cambodia. But as of June 14, 2020, only 128 cases of COVID-19 have been identified in the country. Many of these cases have been from people who had traveled in Europe. Researchers want to do antibody tests on blood from a sampling of people in Phnom Penh to learn the infection risks for people in the greater Phnom Penh area.

Objective:

To estimate the level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the blood of people living in Phnom Penh, Cambodia.

Eligibility:

Healthy males and females age 18-65 living in Phnom Penh since January 2020.

Design:

A mobile unit will travel to schools, shopping areas, parks, and pagodas around Phnom Penh.

Participants will be screened with questions about their age and where they live. They will have blood taken via fingerstick. About 80 uL of blood will be taken. It will be tested for SARS-CoV-2. This visit will take about 30 minutes.

If the test result is positive, participants will be contacted by phone. They will be asked to have a second blood draw. This time, 20 mL of blood will be taken. They can have this visit at their home or in a clinic. This visit will take about 30 minutes.

If a participant has an adverse event, the mobile units and at-home units will have the tools needed to aid the participant. If needed, the participant will be sent to a nearby clinic.

Description:

This is a cross-sectional study performed annually over 3 years to procure blood samples by fingerstick from healthy individuals living in the Phnom Penh area to evaluate seroprevalence to SARS-CoV-2. A mobile unit will move between various markets, schools, hospitals, clinics, parks, and other public places with local authority permissions. Participants with a positive result on the screening SARS-CoV-2 ELISA will be contacted via telephone (since there is not reliable mail in Cambodia) and invited to undergo an additional blood draw via venipuncture during a home visit by the mobile team within 180 days of the initial sample collection. This visit may also be conducted by CCDC/CNM/MOH study staff at a local clinic. Up to 10 of their adult household contacts will be invited to enroll and screen at this time via fingerstick for SARS-CoV-2 ELISA as part of an enriched sampling scheme to boost the probability of identifying SARSCoV- 2 immune individuals; those with positive results will be invited to undergo follow-up venipuncture as described above. Venipuncture samples will be used to study the immune responses of Cambodians to the novel coronavirus.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 30, 2021
• Est. primary completion date: September 24, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Stated willingness to comply with all study procedures and availability for the duration of the study.

2. Male or female, aged 18 - 65 years of age.

3. Residing in Phnom Penh since January 1, 2020.

4. Ability to provide consent.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Any acute illness requiring a visit to a clinic or hospital on the same day as study enrollment.

2. Any underlying, chronic, or current medical condition that, in the opinion of the investigator, would interfere with participation in the study (e.g., inability or great difficulty in drawing blood).

Related Conditions & MeSH terms

• COVID-19
• Healthy Volunteers

Locations

Country	Name	City	State
Cambodia	Cambodian Center for Communicable Disease (CCDC), Ministry of Health (MOH)	Phnom Penh
Cambodia	National Malaria Center (CNM), Ministry of Health (MOH)	Phnom Penh

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Cambodia, 

References & Publications (1)

Lang Z, Reiczigel J. Confidence limits for prevalence of disease adjusted for estimated sensitivity and specificity. Prev Vet Med. 2014 Jan 1;113(1):13-22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence or absence of SARSCoV-2 immunoglobulin in participant sera by ELISA optical density change.	Using convenience sampling at randomized points across Phnom Penh, ELISAs to the SARS-CoV-2 full-length spike and ribonucleocapsid protein (RNP) antigens will be used as these are the most sensitive and specific to be interpreted in the setting of any background noise introduced by Cambodian sera, and because they are less expensive and amenable to high-throughput processing.	Enrollment Day 1 (and Study Visit 2 if applicable)